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O B J E C T I V E S This study sought to evaluate the impact of chronic kidney disease (CKD) on coronary
atherosclerotic plaque composition, morphology, and outcomes in patients with acute coronary syndromes (ACS).
B A C KG ROUND CKD patients presenting with ACS are at increased risk for adverse events.
Whether or not this increased risk reﬂects differences in coronary plaque composition remains unknown.
METHOD S In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary
Tree) study, patients presentingwith ACS inwhompercutaneous coronary interventionwas successful underwent
3-vessel grayscale and radiofrequency intravascular ultrasound imaging. Lesions were prospectively characterized,
and patients were followed for a median of 3.4 years. We conducted a patient-level and lesion-level analysis of
study participants by comparing intravascular ultrasound parameters of untreated nonculprit lesions in patients
with and without CKD.
R E S U L T S Patients with CKD (n  73, 11.3%) were older, more often female and diabetic compared
to those without CKD (n 573). Nonculprit lesions in patients with (n 280) versus without (n 2,390)
CKD were more likely to have plaque burden70% (11.8% vs. 8.5%, p 0.05) and minimal luminal area
4.0 mm2 (25.9% vs. 19.2%, p  0.005). The percentage of plaque comprised of necrotic core (15.0% vs.
13.0%, p 0.0001) anddense calcium (8.2%vs. 6.4%, p 0.0001)was higherwhile ﬁbrous tissue (57.7%vs. 59.8%,
p 0.0001) was lower in CKD versus non-CKD lesions. The 3-year composite rate of cardiac death, cardiac arrest,
ormyocardial infarction (15.1% vs. 3.3%, p 0.0001)was signiﬁcantly higher in patientswith than in thosewithout
CKD, although there were no differences in the rates of events adjudicated to nonculprit lesions.
CONC L U S I O N S Following percutaneous coronary intervention of all culprit lesions in ACS,
patients with versus without CKD have more extensive and severe atherosclerosis remaining in their
coronary tree with plaque composed of greater necrotic core and less ﬁbrous tissue. These inﬂuences
resulted in nonsigniﬁcantly different rates of non-culprit lesion–related adverse events, although cardiac
death, arrest, or myocardial infarction were more common in patients with CKD. (J Am Coll Cardiol Img
2012;5:S53–61) © 2012 by the American College of Cardiology Foundation
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S54atients with chronic kidney disease (CKD)
presenting with an acute coronary syndrome
(ACS) are at substantially increased risk for
adverse fatal and nonfatal cardiovascular events
ompared with those patients with preserved renal
unction (1–3). This excess risk persists despite
reatment with contemporary pharmacotherapy and
arly revascularization (4) and is not accounted for
y traditional risk factors (5). Classically, the in-
reased cardiovascular risk among patients with
See page S73
advanced renal failure on dialysis has been attrib-
uted to a state of “accelerated atherosclerosis” (6).
Whether this is true in the much larger group of
patients with less advanced CKD remains
unknown. In this regard, several recent
studies using both invasive and noninva-
sive imaging modalities have suggested
that there are no differences in either the
extent or progression of atherosclerosis
between patients with and without CKD
(7,8). Clarifying this issue is clinically
relevant as up to 40% of all patients presenting
with ACS have some degree of renal impair-
ment (2,3). The detection of high-risk plaque
subtypes and underlying coronary atheroscle-
rotic plaque composition is now possible with
grayscale and radiofrequency intravascular ul-
trasound (IVUS) (9,10). Differences in IVUS-
related parameters of coronary atherosclerosis
in patients with versus without CKD might
provide important insights into the increased
risk of these patients. Accordingly, we sought
to compare coronary plaque extent, morphol-
ogy, composition, and clinical outcomes
in patients enrolled in the PROSPECT (Provid-
ing Regional Observations to Study Predictors of
Events in the Coronary Tree) study according to
baseline renal function.
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The PROSPECT study design, major inclusion
and exclusion criteria, endpoints, and definitions
have been previously described in detail (11,12) and
results presented (13–18). In brief, 697 patients
with ACS (ST-segment elevation myocardial in-
farction beyond 24 h [STEMI], non-STEMI, or
unstable angina) undergoing percutaneous coronary
intervention (PCI) of 1 or 2 major epicardial
coronary arteries underwent 3-vessel multimodality
intracoronary imaging (quantitative coronary an-
giography, grayscale IVUS imaging, and radiofre-
quency IVUS [virtual histology-intravascular ultra-
sound (VH-IVUS), Volcano Corporation, San
Diego, California]) in order to prospectively char-
acterize the proximal 6 to 8 cm of the coronary tree
prior to longitudinal follow-up. Patients were en-
rolled (and imaging was performed) only after
performance of successful and uncomplicated PCI
of all coronary lesions responsible for the index
event, and after completion of any other planned
interventions. Exclusion criteria included serum
creatinine 2.5 mg/dl, presentation with hypoten-
sion, shock or left ventricular ejection fraction
30%, left main coronary artery culprit lesion, or
necessity for PCI in all 3 major epicardial coronary
vessels. Patients with moderate to severe elevations
of serum creatinine (2.5 mg/dl) were excluded to
minimize risk for further renal deterioration follow-
ing additional contrast exposure during post-PCI
IVUS imaging. Serum creatinine, fasting lipid
panel and glucose, hemoglobin A1c, and high-
sensitivity C-reactive protein were measured at
baseline. The present study includes patients in
whom serum creatinine was measured at baseline
and whose data was available to determine renal
function (n  646).
Estimated glomerular filtration rate (eGFR) was
calculated using the Modification of Diet in Renal
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ACS acute coronary
syndrome(s)
CKD chronic kidney disea
CSA cross-sectional area
eGFR estimated glomerul
filtration rate
IQR interquartile range
IVUS intravascular ultraso
MACEmajor adverse card
events
PCI percutaneous coronar
intervention
STEMI ST-segment elevat
myocardial infarction
TCFA thin-cap
fibroatheroma(s)
VH-IVUS virtual histologyr 16, 2011, accepted December 30, 2011.
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S55Disease formula and CKD was defined as an eGFR
60 ml/min/1.73 m2 (19). Patients underwent clini-
al follow-up at 30, 180, and 365 days, and then yearly
or at least 2 years (median follow-up was 3.4
ears). An independent clinical events committee
linded to baseline features and imaging results
djudicated all clinical events as due to recurrence
t the original treated (culprit) lesion, at a previ-
usly untreated nonculprit lesion, or at an unde-
ermined lesion location (when follow-up an-
iography was not performed). All baseline and
ollow-up angiograms and IVUS images were
nalyzed at an independent core angiographic
aboratory by technicians who were blinded to
linical outcomes (Cardiovascular Research
oundation, New York, New York). Angio-
raphic qualitative and quantitative measure-
ents were obtained for the entire coronary tree.
ll angiographic lesions with at least 30% visible
iameter stenosis were analyzed. An IVUS lesion
as defined as at least 3 consecutive frames with
plaque burden of at least 40%. Such lesions were
urther classified by means of VH-IVUS as one of
he following: thin-cap fibroatheroma (TCFA),
hick-cap fibroatheroma, pathological intimal
hickening, fibrotic plaque, or fibrocalcific plaque
11,20). Each grayscale and VH-IVUS frame and
esion was coregistered to the angiographic road-
ap using fiduciary branches for alignment, as
reviously described (11,20).
The primary endpoint of interest in the PROSPECT
tudy was nonculprit lesion–related major adverse
ardiac events (MACE) defined as the composite of
ardiac death, cardiac arrest, myocardial infarc-
ion, or rehospitalization due to unstable or
rogressive angina. Cardiac death was defined as
eath due to immediate cardiac cause and in-
luded unwitnessed death and death of unknown
ause. Stent thrombosis was defined using the
cademic Research Consortium criteria as defi-
ite or probable (21). The timing of stent throm-
osis following index PCI was further catego-
ized as acute (24 h), subacute (1 to 30 days), and
ate (30 days to 1 year).
The study was approved by the institutional review
oard at each participating center, and all patients
igned informed, written consent. Informed consent
as obtained after the patient was stabilized prior to
he catheterization procedure.
Statistical analysis. Baseline demographics, imaging
characteristics, and outcomes were compared ac-
cording to the presence of CKD. Categorical
variables were summarized using percentages andcounts and were compared using chi-square tests
or Fischer exact test (cell size 5) where appro-
priate. Continuous variables were summarized as
median with interquartile range or mean  SD
and compared using the nonparametric Wilcoxon
rank sum test. Multivariable analyses using CKD
lesions as exposures of interest were performed
using generalized estimating equations, which
allowed for simultaneous adjustment of both patient-
and lesion-level variables. This method also controls
for correlated data as multiple lesions can arise from
the same patient. Outcomes were summarized as
Kaplan-Meier estimates and compared using log-rank
tests. A p value of 0.05 was considered statistically
significant. All statistical analyses were performed
using SAS (version 9.2, SAS Institute Inc., Cary,
North Carolina).
Table 1. Baseline Characteristics According to the Level of Rena
eGFR (ml/min/1.
<60
(n  73) (n
Age, yrs 68.2 10.8 57.
Male 58.9
Diabetes mellitus 24.7
White race 93.3
Body mass index, kg/m2 29.8 5.2 28.
Prior myocardial infarction 11.0
Congestive heart failure 5.5
History of angina 20.9
Family history of coronary artery disease 42.2
Hypertension requiring medication 72.6
Hypercholesterolemia requiring medication 55.4
History of tobacco use within 1 month 34.3
Prior cardiac intervention 15.1
Statin use on admission 34.2
Clinical presentation
STEMI beyond 24 h 16.4
Non-STEMI 79.5
Unstable angina 4.1
eGFR, ml/min/1.73 m2 51.7 6.9 91.
Total cholesterol 169.5 43.0 176.
HDL-cholesterol 41.6 15.1 41.
LDL-cholesterol 93.4 39.4 106.
Triglycerides 181.1 161.4 149.
Fasting plasma glucose 110.4 30.8 110.
C-reactive protein 17.90 31.38 18.1
Number of angiographic lesions per patient* 2.81 2.09 2.5
3-vessel coronary artery disease* 34.2
Values are mean  SD or %. *Nonculprit lesions with diameter stenosis 30%
eGFR  estimated glomerular ﬁltration rate; HDL  high-density lipoprotl Function
73 m2)
p Value
>60
 573)
6 11.0 0.0001
77.8 0.0004
16.5 0.08
92.5 1.00
8 5.6 0.01
9.8 0.76
1.6 0.05
23.4 0.65
45.0 0.67
43.5 0.0001
42.9 0.057
50.3 0.01
10.8 0.28
45.5 0.07
30.2 0.01
66.1 0.02
3.7 0.75
8 21.5 0.0001
1 42.4 0.13
1 13.0 0.61
7 36.3 0.003
3 95.4 0.46
0 33.0 0.70
0 29.70 0.92
2 1.90 0.23
28.9 0.34
by visual estimation.
ein; LDL  low-densitylipoprotein; STEMI  ST-segment elevation myocardial infarction.
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Patients and baseline characteristics. Among the 646
patients in the present analysis, 73 (11.1%) patients
had CKD, and 573 (88.7%) patients had normal
and Radiofrequency IVUS Parameters and Plaque Composition
ents With Versus Without CKD
eGFR (ml/min/1.73 m2)
p Value
<60
(n  218)
>60
(n  1,700)
A, mm3/mm 15.62 5.84 16.26 5.93 0.06
CSA, mm3/mm 7.98 3.18 8.40 3.25 0.03
and media CSA, mm3/mm 7.64 3.10 7.86 3.03 0.14
% 48.8 6.3 48.3 5.8 0.22
US
c core CSA, mm3/mm 0.61 0.50 0.56 0.51 0.02
calcium CSA, mm3/mm 0.35 0.40 0.27 0.33 0.0001
tissue CSA, mm3/mm 2.48 1.50 2.63 1.54 0.08
ty CSA, mm3/mm 0.89 0.84 0.97 0.84 0.07
15.0 8.9 13.0 8.7 0.0001
% 8.2 6.7 6.4 6.6 0.0001
57.7 8.8 59.8 9.6 0.0001
19.1 10.8 20.9 11.9 0.03
D.
y disease; CSA cross-sectional area; EEM external elastic membrane; IVUS
nd; MLA  minimal luminal area.
and Radiofrequency IVUS Parameters and Plaque Composition
ents With Versus Without CKD
eGFR (ml/min/1.73 m2)
p Value
<60
(n  280)
>60
(n  2,390)
m 16.77 14.39 15.66 13.98 0.08
14.32 5.90 14.96 5.81 0.04
6.05 2.88 6.51 2.89 0.002
ia CSA, mm2 8.27 3.82 8.44 3.68 0.23
% 57.3 9.8 56.2 9.1 0.07
diameter, mm 2.45 0.56 2.56 0.57 0.001
ex 0.90 0.15 0.92 0.15 0.04
US
re, mm3 11.61 18.03 10.18 15.17 0.03
ium, mm3 6.78 11.79 5.25 9.46 0.0005
ue, mm3 44.62 55.85 45.53 59.08 0.98
mm3 14.45 19.97 15.86 23.20 0.73
25.0 22.4 0.33
41.8 37.8 0.19
30.4 36.0 0.06
1.4 2.6 0.22
D or %. *Grayscale measurements taken at MLA site.
inal area; PIT  pathologic intimal thickening; TCFA  thin-cap ﬁbroatheroma;
broatheroma; other abbreviations as in Tables 1 and 2.renal function. Median (interquartile range [IQR])
estimated glomerular filtration rate in patients with
and without CKD were 53.8 (IQR: 47.2 to 57.1)
ml/min/1.73 m2 and 88.7 (IQR: 75.2 to 103.4)
ml/min/1.73 m2, respectively.
Baseline characteristics stratified by CKD are pre-
sented in Table 1. In addition to being older, patients
with CKD were more likely to be women, diabetic,
have higher body mass index, and have a history of
congestive heart failure. Other cardiovascular risk
factors, including hypercholesterolemia and hyperten-
sion, were more common in patients with CKD.
Presentation with recent STEMI was less frequent
whereas non-STEMI was more common in CKD
patients. The number of angiographic lesions as de-
termined by quantitative coronary angiography per
patient and the frequency of 3-vessel disease were
similar in CKD and non-CKD groups (Table 1).
Rates of drug-eluting stent use (68.1% vs. 63.4%, p
0.44) and bare-metal stent use (31.9% vs. 34.7%, p 
0.64) during PCI did not differ by CKD status.
Vessel-level IVUS analysis. The total number of ves-
sels that underwent multimodality imaging in pa-
tients with and without CKD were 218 and 1,700,
respectively (Table 2). Mean external elastic mem-
brane and lumen cross-sectional area (CSA) (nor-
malized for imaged length) were smaller in CKD
vessels and mean plaque and media CSA did not
differ between groups. By radiofrequency IVUS, the
percentage of plaque consisting of dense calcium
and necrotic core was higher whereas the percent-
age of fibrous and fibrofatty volume was less in
CKD versus non-CKD vessels (Table 2).
Lesion-level IVUS analysis. By IVUS, 280 discrete
onculprit lesions were characterized in the 73 pa-
ients with CKD, and 2,390 lesions were evaluated in
he 573 patients without CKD. As shown in Table 3,
esions in patients with CKD were longer and had
reater plaque burden and smaller luminal areas. The
requencies of lesions with a minimum luminal area
4.0 mm2, plaque burden 70%, and lesion length
greater than the median of 11.2 mm were greater in
patients with CKD compared to those without CKD
(Fig. 1). The external elastic membrane area and
remodeling index were also smaller in the CKD versus
non-CKD lesions. Plaque composition also varied by
level of renal function with greater necrotic core and
dense calcium in CKD lesions. There were no signif-
icant differences in the frequency of lesion classifica-
tion by radiofrequency IVUS in patients with versus
without CKD. The percentage of lesions with a
necrotic core volume 10% (median) was signifi-Table 2. Grayscale
in Vessels in Pati
Grayscale IVUS
Average EEM CS
Average lumen
Average plaque
Plaque volume,
Radiofrequency IV
Average necroti
Average dense
Average ﬁbrous
Average ﬁbrofat
Necrotic core, %
Dense calcium,
Fibrous tissue, %
Fibrofatty, %
Values are mean  S
CKD chronic kidneTable 3. Grayscale
in Lesions in Pati
Grayscale IVUS*
Lesion length, m
EEM CSA, mm2
MLA, mm2
Plaque and med
Plaque burden,
Minimum lumen
Remodeling ind
Radiofrequency IV
Total necrotic co
Total dense calc
Total ﬁbrous tiss
Total ﬁbrofatty,
TCFA, %
ThCFA, %
PIT, %
Fibrotic, %
Values are mean  S
MLA  minimal lumcantly higher while those with a fibrous tissue volume
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S5760% (median) was lower in patients with versus
without CKD (Fig. 2).
By multivariable analysis, lesions in patients with
CKD versus those in patients without CKD were
more likely to have a plaque burden 70% and
minimum luminal area 4.0 mm2, whereas the asso-
ciation between CKD lesion and long length
(greater than the median of 11.2 mm) was atten-
uated following adjustment (Table 4). After mul-
tivariable adjustment, CKD lesions were signifi-
cantly more likely to be composed of necrotic core
volume 10% (median) and less likely to consist of
fibrous tissue volume60% (median) (Table 4). As
calcification can interfere with the radiofrequency
IVUS interpretation of plaque composition, these
analyses were repeated after excluding lesions with
dense calcium percentage greater than the 75th
percentile yielding similar results. There was a
nonsignificant 1.47-fold higher odds for CKD le-
sion classification as a TCFA (Table 4).
Follow-up adverse events. As shown in Table 5,
patients with versus those without CKD had
higher cumulative 3-year rates of cardiac death
and composite cardiac death, arrest, or myocar-
dial infarction. All-cause mortality was also sig-
nificantly higher in CKD than in non-CKD
patients (12.0% vs. 2.5%; p  0.0001). The
frequency of rehospitalization for unstable or
progressive angina did not differ significantly
between the 2 groups, whereas the overall
MACE was significantly greater in patients with
versus without CKD (31.7% vs. 19.2%; p 
0.01). Although the incidence of nonculprit or
culprit adverse events did not differ significantly
between groups, indeterminate events were more
common among CKD than non-CKD patients
(12.5% vs. 1.3%; p  0.0001).
D I S C U S S I O N
In the present analysis of 646 patients with ACS
who underwent successful PCI followed by 3-vessel
grayscale and radiofrequency IVUS, we detected
important differences in the extent of coronary
atherosclerosis and coronary plaque morphology
between patients with and without CKD. Lesions
in CKD patients were longer with greater luminal
encroachment and higher plaque burden compared
with their non-CKD counterparts. Moreover, cor-
onary atherosclerotic plaque composition assessed
with radiofrequency IVUS demonstrated greater
necrotic core and dense calcium with less fibrous
tissue in CKD versus non-CKD lesions, whereasthere were no significant differences in lesion clas-
sification. Nonculprit lesion–related MACE oc-
curred with similar frequency during 3-year
follow-up in patients with and without CKD,
although CKD patients had significantly greater
overall rates of all-cause and cardiac death and
composite cardiac death, arrest, or myocardial
infarction. In aggregate, our results suggest that
renal dysfunction not only results in greater
coronary atherosclerotic plaque burden and lumi-
nal encroachment, but it may also modulate
coronary atherosclerotic plaque composition to a
less stable phenotype. These data, therefore, pro-
vide novel insight into mechanisms of greater
atherothrombotic risk in CKD patients present-
ing with ACS.
Existing data evaluating coronary atherosclerosis
in CKD patients using imaging modalities other
than conventional angiography are sparse. Two
small reports involving patients without ACS who
Figure 1. Measures of Lesion Severity in Patients With and With
CKD  chronic kidney disease; MLA  minimal luminal area.
Figure 2. Frequency of CKD and Non-CKD Lesions With Radiofr
Derived TCFA, Percentage Necrotic Core Volume >10% (Median
Percentage Fibrous Tissue Volume >60% (Median)out CKDequency-
) andCKD  chronic kidney disease; TCFA  thin-cap ﬁbroatheroma(s).
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S58underwent conventional (grayscale) IVUS reported
that the luminal CSA was smaller in CKD than in
non-CKD lesions (7,8). Similarly, we also found
that a minimum lumen area 4.0 mm2 was signif-
cantly more common in CKD lesions (odds ratio:
.60, 95% confidence interval: 1.13 to 2.27). These
ndings are clinically relevant as a smaller luminal
Table 4. Multivariable Adjusted OR (95% CI) for the Relationshi
Radiofrequency-IVUS Parameters*
MLA <4.0 mm2
CKD lesion 1.60 (1.13–2.27) p 0.009
R
TCFA
CKD lesion 1.47 (0.90–2.39) p 0.12
*In addition to patient-level variables, models were adjusted for the following
 media CSA, dense calcium CSA, and percentage dense calcium volume. †D
percentage ﬁbrous tissue volume  median (60%).
CI  conﬁdence interval; OR  odds ratio; other abbreviations as in Tables 2
umulative Outcomes in Patients With Versus Without CKD
eGFR (ml/min/1.73 m2)
p Value
<60
(n  73)
>60
(n  573)
31.7 (21) 19.2 (101) 0.01
, arrest, or MI 15.1 (10) 3.3 (17) 0.0001
9.1 (6) 0.8 (4) 0.0001
1.4 (1) 0.4 (2) 0.22
9.0 (6) 2.5 (13) 0.003
alization* 21.9 (14) 17.1 (90) 0.31
s, deﬁnite or probable 9.1 (6) 2.5 (13) 0.003
related events
14.2 (9) 11.2 (58) 0.44
, arrest, or MI 1.5 (1) 0.8 (4) 0.50
0.0 (0) 0.0 (0) N/A
alization* 12.7 (8) 10.4 (54) 0.55
ed events
18.1 (12) 12.3 (65) 0.16
, arrest, or MI 5.9 (4) 1.7 (9) 0.02
1.5 (1) 0.0 (0) 0.004
alization* 14.1 (9) 11.9 (64) 0.48
s, deﬁnite or probable 5.9 (4) 1.7 (9) 0.02
nts
12.5 (8) 1.3 (7) 0.0001
, arrest or MI 9.3 (6) 0.8 (4) 0.0001
7.7 (5) 0.8 (4) 0.0001
alization* 3.4 (2) 0.6 (3) 0.03
s, deﬁnite or probable 3.3 (2) 0.8 (4) 0.08
yed as Kaplan-Meier estimate percentages (n events). *Repeat hospitalization
ogressive angina.
erse cardiac event(s); MI  myocardial infarction; N/A  not available; othercbles 1 and 2.SA not only confers greater ischemic potential
22,23), but it might also indicate predisposition to
ardiac death. In an autopsy series, Burke et al. (24)
ound severe luminal stenosis without superimposed
hrombus in 54 of 113 men (47%) who died suddenly,
uggesting that nonthrombotic mechanisms, such as
rrhythmias, may underlie many cases of sudden
ardiac death in the setting of severe luminal stenosis.
iven the increased frequency of severe stenoses in
atients with CKD (which are often angiographically
napparent), such a mechanism may contribute to the
orsened prognosis of CKD patients.
In addition to greater luminal encroachment, we
lso found that the overall extent of coronary athero-
clerosis was greater in CKD than in non-CKD
atients. By IVUS, CKD lesions were longer and
ore likely to have plaque burden 70%. These
ndings are consistent with several smaller studies
ocumenting a greater burden of angiographic coro-
ary artery disease in CKD than in non-CKD pa-
ients presenting with ACS (4,25). As greater plaque
urden was identified in PROSPECT to be a powerful
redictor of subsequent lesion-related events (11),
his finding might place CKD patients at higher
isk for future ACS. In contrast to the present
eport in patients with ACS, other studies have
ound no significant differences in atherosclerotic
urden between non-ACS patients with and with-
ut renal impairment (7,8,26,27).
Using radiofrequency IVUS, we identified several
ifferences in coronary atherosclerotic plaque com-
osition between patients with and without CKD.
ur findings of higher amounts of dense calcium in
KD lesions is not surprising given the strong and
stablished association between renal insufficiency
nd increased coronary calcification (28), possibly
ue to secondary hyperparathyroidism. A novel
nding from the present analysis, however, is that,
etween CKD Versus Non-CKD Lesions and Grayscale and
ayscale IVUS Variables
aque Burden >70% Lesion Length >11.2 mm
(0.95–2.20) p 0.085 1.14 (0.84–1.55) p 0.39
frequency IVUS Variables
ecrotic Core Volume† % Fibrous Tissue Volume†
(1.04–2.51) p 0.03 0.67 (0.48–0.92) p 0.01
n-level covariates: TCFA, ThCFA, ﬁbrotic plaque, EEM CSA, luminal CSA, plaque
dent outcomes were percentage necrotic core volume  median (10%) and
3.p B
Gr
Pl
1.45
adio
% N
1.62
lesio
epenTable 5. 3-Year C
All events
MACE
Cardiac death
Cardiac death
Cardiac arrest
MI
Repeat hospit
Stent thrombosi
Nonculprit lesion–
MACE
Cardiac death
Cardiac death
Repeat hospit
Culprit lesion-relat
MACE
Cardiac death
Cardiac death
Repeat hospit
Stent thrombosi
Indeterminate eve
MACE
Cardiac death
Cardiac death
Repeat hospit
Stent thrombosi
Event rates are displa
due to unstable or pr
MACE  major advompared with non-CKD lesions, CKD lesions
l
w
f
s
f
l
F
a
m
m
c
c
o
e
i
p
(
t
e
w
T
n
c
a
C
w
s
3
s
t
c
b
l
p
p
w
n
s
p
h
s
r
a
c
s
g
c
t
a
f
w
s
s
s
f
t
r
S
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 5 3 – 6 1
Baber et al.
CKD and Coronary Atherosclerotic Plaque
S59were composed of greater necrotic core and less
fibrous tissue, resulting in a higher, albeit not
statistically significant, TCFA frequency. These
findings suggest modulation of atherosclerotic
plaque composition in the setting of CKD and are
consistent with earlier reports examining similar
associations in different vascular territories. Using
integrated backscatter IVUS, for example, Miyagi
et al. (29) demonstrated greater lipid and less
fibrous tissue volume in a series of 89 patients
undergoing elective PCI. In a retrospective study of
114 patients undergoing carotid endarterectomy,
Pelisek et al. (30) found that collagenous fibers in
carotid plaque were significantly less frequent in
CKD versus non-CKD patients (39.2% vs. 54.6%,
p  0.001). Although these reports were limited by
ack of adequate adjustment and potential for bias,
e conducted extensive multivariable adjustment
or both clinical and lesion-level differences in our
tatistical models. Moreover, our results with radio-
requency IVUS did not change after excluding
esions with the most severe levels of calcification.
inally, all images in the PROSPECT study were
nalyzed in a blinded core lab, thereby minimizing
easurement bias.
Our findings suggest unique and independent
echanisms not accounted for by traditional
ovariates that may alter atherosclerotic plaque
omposition in the setting of CKD. Serum levels
f matrix metalloproteinases, for example, are
levated in patients with moderate to severe renal
mpairment (30,31) and are associated with
laque progression and fibrous cap degradation
32,33). In addition, experimental data suggest
hat CKD potentiates foam cell generation by
nhancing macrophage entry into the vascular
all and inhibiting cholesterol efflux (34,35).
hese putative pathways provide a biologic ratio-
ale for our clinical observations of greater ne-
rotic core and less fibrous tissue in coronary
therosclerotic plaque from CKD versus non-
KD lesions. Further investigation is clearly
arranted to fully characterize the unique athero-
clerotic phenotype of CKD.
Consistent with earlier studies, the cumulative
-year rates of all-cause and cardiac mortality were
ubstantially higher in CKD than non-CKD pa-
ients (1,26,36). Adverse events attributable to non-
ulprit lesions, however, did not differ significantly
etween the 2 groups. Conversely, indeterminate
esions were responsible for greater rates of MACE,
articularly cardiac death, during follow-up among
atients with CKD. We are unable to determine rhether or not these events were the result of
onculprit lesion plaque rupture or culprit-lesion
tent thrombosis, because angiography was not
erformed in these patients. The exact etiology of
igher cardiac death in CKD patients in the present
tudy, therefore, remains speculative based on our
esults.
Study limitations. Relatively few patients had CKD,
nd the number of adverse events in the CKD
ohort was small. Therefore, the present results
hould be considered exploratory and hypothesis
enerating. Patients with severe renal insuffi-
iency were also excluded from enrollment, and
hus the CKD cohort represents mild to moder-
te renal dysfunction. We did not assess renal
unction at follow-up, and thus some patients
ith acute kidney injury may have been misclas-
ified as CKD. Nor was urinary albumin mea-
ured, which might have allowed further risk
tratification. VH-IVUS may overestimate the
requency of TCFA as IVUS has an axial resolu-
ion of 150 m, whereas the pathologic defi-
nition of TCFA typically requires cap thickness
65 m (37). Additional limitations include lack
of information on infarct size and ST-segment
resolution following PCI, which might also con-
tribute to different rates of MACE between CKD
and non-CKD in the setting of myocardial in-
farction. Although patients with severe left ven-
tricular dysfunction (ejection fraction 30%)
were excluded from the present study, we were
unable to evaluate the differences in moderate left
ventricular dysfunction between CKD and non-
CKD groups, as this information was not col-
lected. Another limitation is the lack of propen-
sity matching in our statistical methods.
C O N C L U S I O N S
Despite these limitations, the present report is the
most comprehensive and detailed characterization
of coronary atherosclerotic plaque morphology in
CKD patients presenting with ACS using a vali-
dated in vivo imaging modality, which has been
shown to predict future lesion-specific cardiac
events (11). As cardiovascular risk is significantly
increased in patients with renal dysfunction, particu-
larly in the setting of ACS, our findings merit addi-
tional prospective evaluation and clinical correlation.
Reprint requests and correspondence: Dr. Roxana Meh-
an, Cardiovascular Research Foundation, 111 East 59th
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